The aim of the study was to investigate genetic polymorphism in apoptotic gene, 
II. Materials And Methods

Study design and study subjects
This retrospective case-control study comprised 270 histopathologically proven cases of urinary bladder cancer and 252 cancer-free controls. Peripheral blood samples from patients with urinary bladder cancer, treated at Advanced Urology Centre (AUC) of the Post Graduate Institute of Medical Education and Research (PGIMER), Chandigarh, were collected during routine investigations. The ethical clearance for the present study was obtained from the Institute's Ethics Committee. Cases having HIV, allergies and other cancers, or patients having received chemotherapy were excluded. Informed consents were obtained from all the participants. Data with respect to their age, sex, smoking status, alcohol consumption, occupational status, area inhabited and eating habits were recorded. In patients with bladder tumor, the stage and grade of the tumor were noted.
Genotype analysis
Peripheral blood samples (2-4 ml) were collected from cases and controls in EDTA-coated vials. Genomic DNA was subsequently extracted from peripheral blood lymphocytes by the standard phenolchloroform method. The BCL-2 C-938A polymorphism was then determined by PCR-RFLP assay as per the conditions given in Table I (Fig. I) . A mismatch was introduced near the 3' end of each of the primers, close to the mutation of interest, to create an artificial restriction site in the PCR product (PIRA-PCR -Primer Introduced Restriction Analysis-PCR) (Ke et al., 2001) . Independent repetition of genotyping in randomly selected samples produced the same results and hence, proved concordance.
Statistical analysis
The power calculations were conducted at 80% with a significance level of 0.05. The sample size used for the present study was adequate. The data showed normal distribution on applying one-sample KolmogorovSmirnov Z test when age was taken as the test variable. The data were age-matched, as confirmed by T-test. The odds ratios (ORs) and 95% confidence intervals (CIs) were obtained using χ 2 test and Fisher-Exact test for categorical variables. The odds ratios were calculated without adjustment for potential confounders, i.e., sex, area, job status, smoking, alcohol consumption and diet. Based on previous studies, occupations related to auto mechanics (Manju et al., 2009 ), agricultural production, livestock and animal specialities; electrical assembly, installation and repair; and health services (Cassidy et al., 2009 ); printing industry, transportation equipment industry, electrical/gas/sanitary services (Samanic et al., 2008) ; were altogether taken under the category of high-risk occupations and the rest under low-risk occupations.
To achieve an adequate sample size with power of study at 80%, the various tumor stages were clubbed together and merged into two groups, i.e., superficial (Ta + T1) and muscle-invasive (T2 + T3 + T4). Both additive and dominant modes of inheritance were considered. The p-values were two-sided. Values less than 0.05 were considered as significant. All analyses were performed using SPSS, version 15.0 and Epi Info, version 3.4.3.
III. Results
The distribution of the genotype and allele frequencies of BCL-2 C-938A polymorphism among cases and controls is summarized in Table II . The allele frequencies were 77.96% for allele C and 22.04% for allele A in the cases. In the control group, the allele frequencies for allele C were 74.6% and for allele A were 25.4%. No significant differences were observed in the genotype frequencies with regard to bladder cancer for the BCL-2 polymorphism on considering either of the models (dominant/additive).
The interaction of BCL-2 C-938A polymorphism with various environmental factors has been summarized in Table III . The AA genotype showed a decreased risk of bladder cancer among smokers (OR = 0.40, 95% CI = 0.19-0.85), hence, showing a protective effect. The AA genotype also showed a significant decreased risk among vegetarians (OR = 0.39, 95% CI = 0.14-1.06) for bladder cancer. The interaction of BCL-2 C-938A polymorphism with each histological subcategory is summarized in Table IV . No significant associations were observed for this polymorphism among any of the stages or grades.
IV. Discussion
No significant differences were observed in the frequencies of BCL-2 genotypes in bladder cancer cases and controls. However, presence of BCL-2 is proposed to confer a growth advantage to tumour cells (Atug et al., 1998; Asci et al., 2001) . BCL-2 overexpression is rare in transitional cell carcinoma (TCC) of the bladder (Kirsh et al., 1998) . It is well known that depending on the tumour type, expression of BCL-2 is related to different biological behaviours. BCL-2 expression may either mediate G o arrest of tumour cells (Cory and Adams, 2002) leading to a decreased tumour growth or act antiapoptotic, thus promoting tumour growth and a less favourable outcome of cancer patients (Cory and Adams, 2002; Zinkel et al., 2006) . In contrast, it has also been shown that under certain conditions apoptosis may be triggered by BCL-2 expression itself (Hanson et al., 2008) . The differential tumour behaviour, however, may be mediated by other biological processes such as angiogenesis and immune response, which have also been shown to be functionally modulated by BCL-2 (Kumar et al., 2008) .
Increased BCL-2 expression is associated with unfavourable outcome in B-cell chronic lymphocytic leukemia (CLL) and prostate cancer (Keshgegian et al., 1998; Faderl et al., 2002) , whereas its expression is related to increased survival in colorectal and breast carcinoma (Ofner et al., 1995; Zhang et al., 1998) . Results were conflicting, in head and neck cancer patients, but the majority of studies had shown increased BCL-2 expression to be associated with a more favourable outcome (Wilson et al., 1996; Homma et al., 1999; Pena et al., 1999) . Moreover, BCL-2 expression is not uniformly distributed among head and neck cancer subsites. According to tumour site, BCL-2 expression varies from 5 to 35%; its highest expression rate is found in oropharyngeal carcinoma (Stoll et al., 2000) . The expression of BCL-2 was increased in most colorectal adenocarcinomas compared with normal mucosal tissue (Hague et al., 1994; Bronner et al., 1995) . Sinicrope et al. (1995) showed spontaneous apoptosis to be reduced in colorectal carcinomas that had high BCL-2 expression compared with tumours with low or absent BCL-2 expression. The mechanisms behind increased or decreased rates of expression are not clear at all.
The chronic lymphocytic leukemia (CLL) cells have been reported to express high levels of BCL-2. Expression generally appeared to be equivalent to or to exceed that in normal peripheral blood lymphocytes, or even that in cells containing the t (14:18) translocation (Hanada et al., 1993 Quantification of the anti-apoptotic protein BCL-2 in patients undergoing neoadjuvant chemotherapy plus radiotherapy for advanced bladder cancer may identify patients who might benefit from neoadjuvant chemotherapy (Cooke et al., 2000) . The BCL-2 protein inhibits apoptosis and is overexpressed by many tumours including breast (Hellemans et al., 1995) , colon (Bronner et al., 1995) , prostate (Krajewska et al., 1996) and tumours of the head and neck (Gallo et al., 1999) . By virtue of its biological activity, it may be associated with a poor prognosis, with resistance to current treatment modalities including radiotherapy, for example, in cervical (Harima et al., 1998) and prostate (Apakama et al., 1996) cancers. The information on the role played by BCL-2 in transitional cell carcinoma (TCC) of the bladder is quite limited and conflicting, with some studies showing an association with a lower tumour grade (King et al., 1996) and less aggressive phenotype (Shiina et al., 1996) . Others have shown the reverse, with expression being greater in higher-stage and higher-grade tumours, thereby, resulting in increased frequency of disease recurrence and higher disease progression rates, leading to shortened survival (Pollack et al., 1997; Kong et al., 1998; Ye et al., 1998) . It is quite possible that these conflicting results have been because of different interactions between the various treatment modalities and apoptotic pathways.
The -938C>A SNP of BCL-2 gene is located within 100 bases from the TP-53 responsive element in the BCL-2 promoter region (Chen et al., 2007) . The BCL-2 -938C allele codes for a putative binding site for Sp-1, which plays an important role in the transcription of numerous genes and which is abolished in the presence of BCL-2 -938A allele (Nuckel et al., 2007) . The A variant genotypes at the position -938 of the BCL-2 promoter may render a better interaction with TP53, leading to a decrease in the BCL-2 expression, an up-regulated programmed cell death or reduced longevity of the transformed cells, and thus a subsequent decrease in the risk of cancer (Chen et al., 2007) . In the present study, the allele C was more in cases whereas, allele A was more in controls, which runs parallel to the above justification. No significant differences were observed in the genotype frequencies with regard to bladder cancer for the BCL-2 polymorphism on considering either of the models.
There is no study available pertaining to BCL-2 938 C/A polymorphism on bladder cancer. Earlier studies on BCL-2 polymorphism and risk of other cancers did not show any significant differences between cases and controls. As both genotype distributions and allele frequencies were not significantly different in patients and controls, there was no evidence for an association of BCL-2 938 genotypes with an increased risk to develop CLL (Nuckel et al., 2007) . Majid et al. (2008) also failed to confirm that the -938C>A polymorphism associates with BCL-2 protein levels and disease progression in CLL. Chen et al. (2007) analyzed the role of BCL-2 (-938C>A) as risk factor for head and neck squamous cell carcinoma (HNSCC) in a large series of Caucasian patients. Risk analysis in the whole-study population revealed no significant differences between genotypes (P = 0.933). Even after liaisons of variant genotypes, no significant results were observed. Lehnerdt et al. (2009) analyzed the -938C>A polymorphism specifically in oropharyngeal squamous cell carcinoma (OSCC), the HNSCC subsite with the highest BCL-2 expression rate, as possible modulator of the clinical course. But, overall analysis of genotype distributions of cases and controls was not significantly associated with the risk for OSCC (P = 0.074). The results of present study are in accordance with these studies. Kidd et al. (2006) , with a relatively small sample size, investigated the role of this SNP in the etiology of prostate cancer and reported a decrease in prostate cancer risk. They found variant allele of BCL-2 -938C>A to be associated with reduced risk of prostate cancer in Caucasians, possibly due to the elimination of an Sp1 binding site, a downregulation of BCL-2 mRNA transcript levels, and unregulated programmed cell death. It was consistent with what was found in another study conducted by Hu et al. (2008) .
Smoking
Teni and colleagues (2002) have analyzed the expression of BCL-2 gene in chewing tobacco-induced oral cancers and oral lesions from India. Their study demonstrated frequent (43-56%) over-expression of BCL-2 in the tobacco chewing associated oral cancers in Indians. In addition, aberrant BCL-2 expression was also demonstrated in a subset (16%) of oral lesions, representing early events in oral tumourigenesis (Teni et al., 2002) .
It is possible that nicotine may be regulating BCL-2 to stimulate cell survival. Mai et al. (2003) reported that nicotine can induce BCL-2 phosphorylation exclusively at the serine-70 site in association with prolonged survival of SCLC H82 cells expressing wild-type, but not the phosphorylation-deficient S70A mutant BCL-2 after treatment with chemotherapeutic agents (cisplatin or VP-16).
Nicotine induces activation of PKCα and the MAPKs ERK1 and ERK2, which are physiological BCL-2 kinases. Furthermore, ET-18-OCH3, a phospholipase C (PLC) inhibitor, blocks nicotine-stimulated BCL-2 phosphorylation and promotes apoptosis, suggesting that PLC may be involved in nicotine activation of BCL-2 kinases (Mai et al., 2003) . Thus, nicotine-induced cell survival results, at least in part, form a mechanism that involves BCL-2 phosphorylation.
A correlation between heavy cigarette smoking and increased expression of BCL-2 in patients with lung, head, or neck cancer suggests that BCL-2 may be a target of carcinogens found in tobacco smoke (Gallo et al., 1995) .
It is possible that nicotine-induced upregulation of the anti-apoptotic activity of BCL-2 results from phosphorylation, because the post-translational modification potently enhances the stability of BCL-2 protein (Dimmeler et al., 1999; Deng et al., 2001 ). Phosphorylation of BCL-2 at Ser 70 stabilizes its heterodimeric interaction with BAX (Deng et al., 2000) , a pro-apoptotic molecule required for cell death (Wei et al., 2001) . The data of Mai and colleagues (2003) supported and extended these findings, because nicotine stimulates not only Ser 70 site BCL-2 phosphorylation but also BCL-2/BAX heterodimerization, a mechanism currently thought to block the death action of BAX (Oltvai et al., 1993) . Since the BCL-2 polymorphism belongs to the promoter region of BCL-2, it is quite possible that it might be affecting the phosphorylation of BCL-2 at Ser 70 site. As BCL-2 AA genotype was found to be protective in smokers, it could be possible that the A allele might be regulating the decrease in BCL-2 phosphorylation.
Diet
The BCL-2 AA genotype had a protective effect among vegetarians. Many studies have been carried out particularly on BCL-2 expression. According to one study, a combination of genistein, quercetin and biochanin-A was significantly more effective than individual compounds or their double combinations in decreasing BCL-2 mRNA expression as well as protein levels in prostate cancer (Kumar et al., 2010) 
V. Conclusion
Although of significant interest, further work is required to determine the frequency of these polymorphisms in larger cohorts of cancer patients and normal individuals, not only in bladder cancer but also in various other cancers, as the literature pertaining to BCL-2 polymorphism is very less. To evaluate whether genotyping of the BCL-2 polymorphism may offer the opportunity to identify responders and non-responders to BCL-2 targeted therapy, prospective clinical trials are necessary. 
